Show simple item record

dc.contributor.authorHjell, Gabriela
dc.contributor.authorRokicki, Jaroslav
dc.contributor.authorSzabo, Attila
dc.contributor.authorHolst, Rene
dc.contributor.authorTesli, Natalia
dc.contributor.authorBell, Christina
dc.contributor.authorFischer-Vieler, Thomas
dc.contributor.authorWerner, Maren Caroline Frogner
dc.contributor.authorLunding, Synve Hoffart
dc.contributor.authorElkjær Greenwood Ormerod, Monica Bettina
dc.contributor.authorJohansen, Ingrid Torp
dc.contributor.authorDjurovic, Srdjan
dc.contributor.authorUeland, Thor
dc.contributor.authorAndreassen, Ole
dc.contributor.authorMelle, Ingrid
dc.contributor.authorLagerberg, Trine Vik
dc.contributor.authorMørch-Johnsen, Lynn Egeland
dc.contributor.authorSteen, Nils Eiel
dc.contributor.authorHaukvik, Unn Kristin Hansen
dc.date.accessioned2023-11-14T09:14:22Z
dc.date.available2023-11-14T09:14:22Z
dc.date.issued2023-09-07
dc.description.abstractBackground Impulsivity is a transdiagnostic feature linked to severe clinical expression and a potential target for psychopharmacological strategies. Biological underpinnings are largely unknown, but involvement of immune dysregulation has been indicated, and the efects of psychopharmacological agents vary. We investigated if impul‑ sivity was associated with circulating immune marker levels and with a range of psychopharmacological treatment regimens in severe mental disorders.<p> <p>Methods Impulsivity was assessed in a sample (N=657) of patients with schizophrenia or schizophreniform disorder (SCZ) (N=116) or bipolar disorder (BD) (N=159) and healthy participants (N=382) using the Barratt Impulsiveness Scale (BIS-11) questionnaire. Plasma levels of systemic immune markers (RANTES, IL-1RA, IL-18, IL-18BP, sTNFR-1) were measured by enzyme immunoassays. Patients underwent thorough clinical assessment, including evaluation of psy‑ chotropic medication. Associations were assessed using linear regressions. <p>Results Impulsivity was positively associated with SCZ (p<0.001) and BD (p<0.001) diagnosis and negatively associated with age (p<0.05), but not signifcantly associated with any of the circulating immune markers indepen‑ dently of diagnostic status. Among patients, impulsivity was negatively associated with lithium treatment (p=0.003) and positively associated with antidepressant treatment (p=0.011) after controlling for diagnosis, psychotropic comedications, manic symptoms, and depressive symptoms. <p>Conclusions We report elevated impulsivity across SCZ and BD but no associations to systemic immune dysregu‑ lation based on the current immune marker selection. The present study reveals associations between impulsivity in severe mental disorders and treatment with lithium and antidepressants, with opposite directions. Future studies are warranted to determine the causal directionality of the observed associations with psychopharmacotherapyen_US
dc.identifier.citationHjell, Rokicki, Szabo, Holst, Tesli, Bell, Fischer-Vieler, Werner, Lunding, Elkjær Greenwood Ormerod, Johansen, Djurovic, Ueland, Andreassen, Melle, Lagerberg, Mørch-Johnsen, Steen, Haukvik. Impulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapy. BMC Psychiatry. 2023;23(1)en_US
dc.identifier.cristinIDFRIDAID 2188406
dc.identifier.doi10.1186/s12888-023-05154-4
dc.identifier.issn1471-244X
dc.identifier.urihttps://hdl.handle.net/10037/31751
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalBMC Psychiatry
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleImpulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)